Literature DB >> 21683258

Using Caenorhabditis elegans to study serpinopathies.

Olivia S Long1, Sager J Gosai, Joon Hyeok Kwak, Dale E King, David H Perlmutter, Gary A Silverman, Stephen C Pak.   

Abstract

Protein misfolding, polymerization, and/or aggregation are hallmarks of serpinopathies and many other human genetic disorders including Alzheimer's, Huntington's, and Parkinson's disease. While higher organism models have helped shape our understanding of these diseases, simpler model systems, like Caenorhabditis elegans, offer great versatility for elucidating complex genetic mechanisms underlying these diseases. Moreover, recent advances in automated high-throughput methodologies have promoted C. elegans as a useful tool for drug discovery. In this chapter, we describe how one could model serpinopathies in C. elegans and how one could exploit this model to identify small molecule compounds that can be developed into effective therapeutic drugs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683258      PMCID: PMC4374434          DOI: 10.1016/B978-0-12-386471-0.00013-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  29 in total

Review 1.  Cellular platforms for HTS: three case studies.

Authors:  Paul A Johnston; Patricia A Johnston
Journal:  Drug Discov Today       Date:  2002-03-15       Impact factor: 7.851

2.  PCR fusion-based approach to create reporter gene constructs for expression analysis in transgenic C. elegans.

Authors:  Oliver Hobert
Journal:  Biotechniques       Date:  2002-04       Impact factor: 1.993

Review 3.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 4.  Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease.

Authors:  David A Rudnick; David H Perlmutter
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

5.  Green fluorescent protein as a marker for gene expression.

Authors:  M Chalfie; Y Tu; G Euskirchen; W W Ward; D C Prasher
Journal:  Science       Date:  1994-02-11       Impact factor: 47.728

6.  SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans: initial characterization of the clade L serpins.

Authors:  Stephen C Pak; Vasantha Kumar; Christopher Tsu; Cliff J Luke; Yuko S Askew; David J Askew; David R Mills; Dieter Brömme; Gary A Silverman
Journal:  J Biol Chem       Date:  2004-01-22       Impact factor: 5.157

7.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

8.  HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Authors:  Paul A Johnston; Jennifer Phillips; Tong Ying Shun; Sunita Shinde; John S Lazo; Donna M Huryn; Michael C Myers; Boris I Ratnikov; Jeffrey W Smith; Ying Su; Russell Dahl; Nicholas D P Cosford; Sergey A Shiryaev; Alex Y Strongin
Journal:  Assay Drug Dev Technol       Date:  2007-12       Impact factor: 1.738

9.  Sequence requirements for myosin gene expression and regulation in Caenorhabditis elegans.

Authors:  P G Okkema; S W Harrison; V Plunger; A Aryana; A Fire
Journal:  Genetics       Date:  1993-10       Impact factor: 4.562

10.  Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z.

Authors:  Sager J Gosai; Joon Hyeok Kwak; Cliff J Luke; Olivia S Long; Dale E King; Kevin J Kovatch; Paul A Johnston; Tong Ying Shun; John S Lazo; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.